BioSpace News Archive

Emergen Research has recently published its latest report titled “Metastatic Cancer Treatment Market By Treatment Type, By Application, By End-Use, Forecasts to 2027.”

The National Kidney Foundation (NKF) and the American Society of Nephrology (ASN) stress the precarious position people with kidney failure, who are immunocompromised, face as the recent Omicron wave continues to spread among patients and staff at dialysis facilities.

Nutra Pharma Corporation, a biotechnology company marketing Nyloxin®, Pet Pain-Away™, Luxury Feet™ and Equine Pain-Away™ in the over-the-counter pain management market and which is also developing treatments for Multiple Sclerosis, Human Immunodeficiency Virus and Pain, announced that the Company’s Chief Executive Officer, Rik J Deitsch, has published a Letter to Shareholders on the Company’s website.

CS Genetics, a privately held genomics-technology company, today announced the appointment of Jeremy Preston, PhD, as Chief Commercial Officer.

Lonza announced today the launch of its new bYlok™ technology platform for the discovery and design of bispecific antibodies.

HeartFlow Holding, Inc., the leader in revolutionizing precision heart care, announced the appointment of Timothy Barabe to its Board of Directors.

Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (“FDA”) to market the Venus BlissMAX device (“BlissMAX”) in the United States.

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2021 financial results will be released on Tuesday, February 1, after the market closes.

Fusion Pharmaceuticals Inc., a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, announced that the compensation committee of the Company’s Board of Directors granted stock option awards to purchase an aggregate of 119,000 shares of its common stock to one employee outside Fusion’s 2020 Stock Option and Incentive Plan.

Amcor plc will announce its Half Year 2022 results for the six months ended 31 December 2021 after the US market closes on Tuesday 1 February 2022.